A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs RPh 201 (Primary)
- Indications Optic nerve disorders
- Focus Therapeutic Use
- Acronyms ION
- Sponsors Regenera Pharma
- 05 Dec 2016 Status changed from recruiting to completed.
- 28 Apr 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2014 New trial record